ROME — The investigational, once-daily, human glucagon-like peptide-1 analog, liraglutide, produced a 1.5 percentage point drop in hemoglobin A1c, as well as significant drops in body weight and blood pressure, in a study of patients with type 2 diabetes who were also taking metformin and rosiglitazone.
PREVIEW